Belgium's largest clinical research center encourages further participation in studies to evaluate vaccines Anima Research Center is currently recruiting participants to participate in a clinical trial for an RSV vaccine by Moderna Alken, Belgium - Sept. 15, 2022: One of Europe's largest leading clinical research centers, Anima Research Center, based in Alken, Belgium, calls

NEW YORK/COPENHAGEN, 7 December 2021 - UNICEF and Clover Biopharmaceuticals Ltd. have signed a long-term agreement for the supply of the Clover COVID-19 vaccine on behalf of the COVAX Facility.

On 1 June, the Anima Research Centre will open a department at the Health Campus in Diepenbeek. This will allow for closer cooperation in the future between Hasselt University and the test centre in Alken, where vaccines are tested.

Last year, Anima Research Center participated in a clinical trial in patients suffering from excessive sleep drive or idiopathic hypersomnia. This is a condition characterized primarily by excessive daytime sleepiness and prolonged sleepiness at night that often causes patients to have difficulty functioning in daily life. Here there was previously no medication

RSV is a major cause of severe respiratory disease in high-risk adults, young children and the immunocompromised. Watch Sarah's story to learn why it's important to monitor for symptoms of RSV, and to seek further testing when things don't seem right.

"The government should show leadership and mandate vaccination with the corona vaccine for everyone." So says Dr. Erik Buntinx of the Anima Research Center in Alken. According to him, the vaccines are the only answer to the corona pandemic. The Alken research center is looking for 200 new subjects for a new study with the booster vaccine and

RARITAN, N.J., September 29, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen's investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in

NEW BRUNSWICK, N.J., September 21, 2021 - Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The safety profile of the vaccine

The Anima Research Center, currently the largest research center in the world where the Janssen vaccine is tested on humans, is opening a new site at UHasselt's Science Park. The new research center will increase the testing capacity for new vaccines. For example, the team will soon start developing a new vaccine against the RSV virus.

It is an illusion to think that we will be rid of it with one or two shots. Perhaps certainly the weak will have to be vaccinated again next year. So says Dr. Erik Buntinx. He heads the Anima Research Center in Alken, currently the largest research center in the world where the Janssen vaccine is being tested.